Clinical Trials Browser

Terminated × Has results × elotuzumab × Clear all

NCT03411031 2023-03-29

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Phase 2 Terminated

18 enrolled 11 charts

Multiple Myeloma